Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma

Chun-Ming Ho\textsuperscript{a,b,c}, Kuen-Tyng Lin\textsuperscript{d}, Roger Shen\textsuperscript{a}, De-Leung Gu\textsuperscript{a}, Szu-Shuo Lee\textsuperscript{a,d}, Wen-Hui Su\textsuperscript{e,f,\ast}, Yuh-Shan Jou\textsuperscript{a,b,d,\ast}

\textsuperscript{a}Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan
\textsuperscript{b}Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan
\textsuperscript{c}Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, 1001 University Road, Hsinchu 300, Taiwan
\textsuperscript{d}Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, Taiwan
\textsuperscript{e}Department of Biomedical Sciences, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung Molecular Medicine Research Center, Chang Gung University, 259 Wen-Hua 1st Road, Kweishan, Taoyuan 333, Taiwan
\textsuperscript{f}Department of Otolaryngology, Chang Gung Memorial Hospital, Linkou, 5 Fu-Hsing Street, Kweishan, Taoyuan 333, Taiwan
\textsuperscript{\ast}Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, Taiwan

\textbf{A R T I C L E   I N F O}

Article history:
Received 18 September 2021
Received in revised form 5 April 2022
Accepted 5 April 2022
Available online 9 April 2022

Keywords:
Comparative genomic analysis
Hepatocellular carcinoma
Prognosis
Sorafenib combination therapy
CENPW
NCAPG

\textbf{A B S T R A C T}

With the increasing incidence and mortality of human hepatocellular carcinoma (HCC) worldwide, revealing innovative targets to improve therapeutic strategies is crucial for prolonging the lives of patients. To identify innovative targets, we conducted a comprehensive comparative transcriptome analysis of 5,410 human HCCs and 974 mouse liver cancers to identify concordantly expressed genes associated with patient survival. Among the 664 identified prognostic comparative HCC (pCHC) genes, upregulated pCHC genes were associated with prognostic clinical features, including large tumor size, vascular invasion and late HCC stages. Interestingly, after validating HCC patient prognoses in multiple independent datasets, we matched the 664 aberrant pCHC genes with the sorafenib-altered genes in TCGA_LIHC patients and found these 664 pCHC genes were enriched in sorafenib-related functions, such as downregulated xenobiotic and lipid metabolism and upregulated cell proliferation. Therapeutic agents targeting aberrant pCHC genes presented divergent molecular mechanisms, including suppression of sorafenib-unrelated oncogenic pathways, induction of sorafenib-unrelated ferroptosis, and modulation of sorafenib transportation and metabolism, to potentiate sorafenib therapeutic effects in HCC combination therapy. Moreover, the pCHC genes NCAPG and CENPW, which have not been targeted in combination with sorafenib treatment, were knocked down and combined with sorafenib treatment, which reduced HCC cell viability based on disruption to the p38/STAT3 axis, thereby hypersensitizing HCC cells. Together, our results provide important resources and reveal that 664 pCHC genes represent innovative targets suitable for developing therapeutic strategies in combination with sorafenib based on the divergent synergistic mechanisms for HCC tumor suppression.

\textcopyright 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hepatocellular carcinoma (HCC) is the main subtype of primary liver cancer and the sixth most common cancer and the fourth leading cause of death of cancer patients worldwide [1]. Most HCC patients are found in developing countries in Asia and Sub-Saharan Africa. However, the incidence of HCC in developed countries, such as the USA, Japan and some European countries, is rising because of increasing cases of hepatitis C virus infection and non-alcoholic steatohepatitis (NASH) associated with metabolic syndrome or diabetes mellitus [2]. Hence, the World Health Organization estimates that more than 1 million patients will die from liver cancers in 2030 [3]. Depending on the tumor burden and liver function of HCC patients, treatments with hepatic surgical resection, local ablation and liver transplantation are the major curative interventions for early HCC patients[4]. Nevertheless, with the vast majority of HCC patients being first diagnosed at the non-
curable advanced stage, patients will receive systemic therapies with antiangiogenic multiple kinase inhibitors and/or metronomic chemotherapeutic drugs as well as immune checkpoint inhibitors [4–7]. Sorafenib is the standard FDA-approved first-line therapeutic drug for the treatment of advanced-stage HCC, and it has a response rate of <10% and a therapeutic benefit of prolonging life by a median of 3 months for HCC patients [8,9]. Although therapeutic response rates exceed 20% in HCC patients after treatment with the newly developed antiangiogenic multiple kinase inhibitors (e.g., lenvatinib) and/or immune checkpoint inhibitors (e.g., nivolumab and atezolizumab) [10–12], applying innovative genomic approaches to identify additional biomarkers for guiding suitable therapies and targets for developing novel therapeutic strategies remains critical for prolonging survival for the majority of HCC patients [4,13].

After applying comprehensive sequencing approaches to the HCC genomes, only a limited number of somatic mutations were revealed as potential therapeutic targets; moreover, frequently observed mutations are not currently applied for predicting therapeutic responses in clinical practice [14,15]. The genetic heterogeneity of HCC genomes could be due to the accumulation of somatic mutations during long-term exposure to divergent etiological risk factors, such as viral hepatitis, alcohol abuse, aflatoxin ingestion and metabolic syndrome. In particular, intratumoral heterogeneity with frequent HCC genomic alterations has been shown to confer selective advantages of cell proliferation, and it is commonly associated with tumor recurrence, drug resistance and metastasis, thus leading to poor outcomes in HCC patients [16–18].

Comparative and integrated cancer genomic approaches are commonly applied to identify cross-species aberrant cancer genes and in best-fit mouse models of cancer subtypes of several cancers to reveal the tumorigenic mechanisms and develop therapeutic approaches to improve therapeutic interventions [19–24]. Notably, limited efforts were applied to reveal the overall consensus of pathophysiological functions shared in human and mouse cancer genomes, reveal the common tumorigenic pathways and predict innovative targets for dissecting the molecular mechanisms underlying combination therapies for therapeutic improvement [22,25].

In this study, we applied the most comprehensive comparative transcriptome analysis to date (to the best of our knowledge) that included large-scale liver cancer transcriptome datasets including 5410 human HCC samples and 974 mouse liver cancers to reveal the major concordant pathophysiological functions in HCC progression. As enriched HCC differentially expressed genes (DEGs) are commonly associated with drug metabolism and cell proliferation [26], we hypothesized that comparative HCC genes associated with patient prognosis might include a large number of known and unknown theranostic targets suitable for sorafenib combination therapies for developing innovative strategies to prolong the lives of HCC patients. Indeed, we identified 664 prognostic comparative HCC (pHCC) genes, ~44% of which have not been thoroughly studied in HCC, uncovered targets for sorafenib combination therapies with divergent molecular mechanisms to synergize HCC tumor suppression, and revealed an innovative oncogenic p38/STAT3 axis that enhances sorafenib tumor suppression for potential improvement of therapeutic interventions in HCC patients.

2. Results

2.1. Identification of 664 pHCC genes associated with patient prognosis

We collected large-scale transcriptome datasets of human HCCs and mouse liver cancers from public databases, including 5410 human HCCs (52 datasets from 23 array platforms, Supplementary Table 1) and 974 mouse liver tumors (52 datasets from 23 array platforms, Supplementary Table 2), for comparative analysis. All human transcriptomes were derived from HCC tumors, with the exception of the cell line transcriptomes. The majority of mouse transcriptomes were annotated as HCC (~70%) or liver cancer (~30%) in genetically modified models with and without carcinogen induction (Supplementary Table 2 for details). After inferring the gene expression intensity based on the log2 tumor/normal ratio and Z score normalization, we generated expression profiles of human HCCs that consisted of 3,339 tumor/normal ratios of 26,182 differentially expressed genes (DEGs) and expression profiles of mouse liver cancer that consisted of 633 tumor/normal ratios of 18,157 DEGs (analysis pipeline in graphic abstract). We then determined the concordant aberrantly expressed comparative DEGs and revealed that 1,904 (766 upregulated and 1,138 downregulated) DEGs participated in both human HCC and mouse liver cancer. To emphasize the clinical value, we matched the 1,904 comparative HCC DEGs with prognostic HCC DEGs in the TCGA.–LIHC dataset and identified 664 pHCC genes for experimental and translational evaluation (Fig. 1A and Supplementary Table 3). Notably, we found that few HCC studies have focused on 293 of 664 (~44%) pHCC genes (labeled “unknown” as HCC genes) based on PubMed searches.

2.2. Validation of the aberrant known and unknown pHCC genes

To validate aberrantly expressed pHCC genes in HCC, we selected two independent HCC cohorts from two different platforms, namely, iCOD (integrated clinical omics database with transcriptomes conducted using Affymetrix HG-U133 plus 2.0 arrays) [27] and TCGA_LIHC (transcriptomes conducted by next-generation sequencing technology, RNA-Seq) [14], to confirm the altered gene expression in HCCs. Consistently, our results showed concordant aberrant pHCC gene expression between two selected transcriptomic datasets (pHCC genes from the meta-analysis results of this study, iCOD and TCGA_LIHC) with a very significant positive correlation (Pearson’s correlation coefficient r > 0.61, P value < 2.2 × 10^-16) (Fig. 1B and Supplementary Fig. 1A and B, and Supplementary Table 4).

To detail the involvement of the 664 pHCC genes in HCC tumor progression, we searched PubMed and found that a total of 354 upregulated (53.3% of 664) pHCC genes, including 219 (62%, orange dots) that were previously reported to be related to HCC and 135 (38%, red dots) that were not previously associated with HCC (Fig. 1A and Supplementary Table 3). The majority of the top 10 known upregulated pHCC genes (orange dots), such as TOP2A, PRC1, and AKR1B10, were studied thoroughly, with multiple reports focusing on their roles in HCC tumor progression and poor prognosis [28–30]. In contrast, the top 10 unknown pHCC genes (red dots) were rarely studied or even had zero HCC results (e.g., RRAGD) in PubMed searches. For the 310 (46.7% of 664) downregulated genes, 152 (49%, sky blue dots) were known to be downregulated, such as TAT, CYP2C9 and SLC01B, and they were associated with better prognosis of HCC patients in some reports [31–33]. On the other hand, 158 unknown and downregulated pHCC genes (51%, blue dots) have been seldom studied or even yielded no search results with HCC, such as CFHR3 and TTC36. Moreover, other known HCC genes that were upregulated (e.g., GPC3, AURKA and others) and downregulated (e.g., CLEC1B, CHBBP and others) were also identified in the majority of HCC samples (as percentages on the x-axis), with differential expression intensities between tumor and normal HCC samples (as percentages on the y-axis) (Fig. 1A and Supplementary Table 3). Interestingly, several pHCC genes were found to have very little or no representation among HCC studies, including CENPW and CENPU (upregulated) as well as OIT3, IDO2, CNDP1 and ANGPTL6 (downregulated),
According to PubMed searches, together, our results provide evidence that the 664 pcHCC genes not only participate in HCC tumorigenesis but are also useful for the development of innovative theranostic biomarkers for therapeutic interventions of HCC.

2.3. Validation of pcHCC genes associated with clinical features and patient survival

To further confirm the aberrant expression of the 664 pcHCC genes involved in altered liver function during tumor progression, we examined their aberrant expression associated with the clinical and demographic characteristics of HCC patients from the iCOD dataset (Supplementary Fig. 2). Consistent with previous reports, aberrant expression of pcHCC genes in HCCs was associated with known independent predictors of patient prognosis, including vein invasion, tumor size, diabetes and late tumor stage [34–36]. Then, we conducted unsupervised clustering to divide the genes into two groups, namely, upregulated and downregulated pcHCC genes. As expected, according to the Kaplan–Meier plot, the cluster of HCC patients with high combined expression of upregulated pcHCC genes in the TCGA-LIHC dataset exhibited worse survival than the cluster of HCC patients with low combined expression, with the comparison of Cox coefficients showing a significant P value (log rank test, P < 0.0001) (Fig. 2A). In contrast, the cluster of HCC patients with high combined expression of downregulated pcHCC genes showed a better prognosis than the cluster of HCC patients with low combined expression in the TCGA-LIHC dataset, with the comparison of Cox coefficients showing a significant P value (log rank test, P = 0.0021) (Fig. 2B).

We also validated the aberrant expression of pcHCC genes individually in association with the prognosis of HCC patients in the TCGA-LIHC dataset, including known (NAPG, ASPM, TOP2A, PRC1, CCNB2, AKR1B10, Kif26A, UBE2T, DCD20 and PBK) and unknown (CENPW, HMMR, CKAP2L, TRIP13 and GINS1) upregulated pcHCC genes associated with poor survival in Kaplan–Meier plots (Fig. 2C and D). In contrast, known (SOCS2, G6, CYP8B1, TAT, LCAT, CYP2C9, CYP2CS, ADH4, SLC22A1 and NAT2) and unknown (HGFAC, TTC36, DNA5E1L3, AKR1D1 and KLKB1) downregulated pcHCC genes were associated with better survival of HCC patients (Fig. 2D and E). Collectively, we concluded that the 664 pcHCC genes are important resources as theranostic biomarkers and targets; thus, their pathological roles in HCC tumor progression should be further investigated and associated therapeutic interventions should be developed to prolong the life of HCC patients.

2.4. Gene set enrichment analysis (GSEA) of 664 pcHCC genes

To reveal the core pathophysiological functions of the 664 pcHCC genes in HCC progression, we compared the functional hallmarks of the GSEA signatures of these genes with two HCC DEGs, including the HCC DEGs from the transcriptomes of human and mouse microarrays and from the TCGA-LIHC datasets. Based on the significance of the functional gene signatures, we found that genes associated with cell proliferation-related hallmarks, including genes for E2F targets, MYC targets, mitotic spindle, and G2M checkpoint, were upregulated, and genes associated with metabolism-related hallmarks, including genes for the metabolism of xenobiotics, bile acids, coagulation, fatty acids, and adipogenesis, were downregulated (Fig. 3A and Supplementary Table 5). To further validate whether aberrant hallmarks of cell proliferation and metabolism play critical roles in the prognosis of HCC patients, we collected cell proliferation-related pcHCC genes (n = 116, Supplementary Table 6) and metabolism-related pcHCC genes (n = 88, Supplementary Table 7) to understand their relationship with the prognosis of HCC patients. Indeed, our results demonstrated that upregulation of cell proliferation-related pcHCC genes and metabolism-related genes was significantly associated with poor (log rank test, P = 0.004) and better (log rank test, P < 0.001) HCC prognosis, respectively (Fig. 3B). Together, our results showed that the core pathological features in the upregulation of cell proliferation and downregulation of certain metabolic pathways, especially lipid and xenobiotic (drug) metabolism-related pathways, presented significant involvement in tumor malignancy in human HCC and mouse liver cancer models.
2.5. Predicting targets for sorafenib combination therapies in pcHCC genes

Based on the 664 pcHCC genes exhibiting aberrant proliferation as known targets of the HCC first-line therapy drug sorafenib [26] and xenobiotic pathways known to have roles in drug metabolism, we hypothesized that pcHCC genes might involve multiple pathways that are correlated with sorafenib-altered HCC expression profiles in patients who received sorafenib therapy and thus may be useful for identifying targets and therapeutic agents for sorafenib combination therapy. In the TCGA-LIHC dataset, 28 patients who received sorafenib treatment and had RNA-Seq transcriptome data were downloaded for the analysis. After matching the sorafenib-altered HCC genes from the TCGA_LIHC dataset with the 664 pcHCC genes, we divided these genes into four possible quadrants, namely, Q1: up/up (n = 205), Q2: down/up (n = 116), Q3: down/down (n = 194), and Q4: up/down (n = 149), which represented the alterations in gene expression relative to the pcHCC genes/sorafenib-altered HCC genes, and the values were calculated as log2 ratios (Fig. 4A and Supplementary Tables 8 and 9). For instance, the representative top 10 known and unknown pcHCC genes were redistributed into four quadrants, as shown with the red lines/rectangles, for scenarios with potential further upregulation (Q1: up/up) and downregulation (Q3: down/down) after sorafenib treatment (Fig. 5A). In contrast, the green lines/rectangles indicate scenarios with opposite changes in expression (Q2: down/up; Q4: up/down) of the HCC genes after sorafenib treatment.

To further validate whether these sorafenib-altered pcHCC genes could be useful as targets in combination therapies, we conducted a GSEA and found that these genes participated in several signaling pathways, including the PI3K/AKT/mTOR, xenobiotic metabolism, angiogenesis, hypoxia and ferroptosis pathways, which were previously reported as sorafenib-related pathways and potential targets for sorafenib combination therapies (Fig. 4B and Supplementary Table 10) [56]. For instance, AKR1B10 (aldo–keto reductase family 1 member B10) in Q1 is known to convert carbonyl compounds on aldehydes or ketones to alcohols for detoxification in the liver, and its upregulation is associated with the prognosis of HCC patients [28]. Because AKR1B10 is upregulated in HCC after sorafenib treatment, combination therapy with an AKR1B10 inhibitor via suppression of the mTOR signaling pathway enhanced the inhibitory effect of sorafenib on HCC xenografts in a nude mouse model (Fig. 4B and Table 1) [43]. In addition, SLC27A5 (in Q3), PCK1 (in Q2), SLC22A1 (in Q2) and SLCO1B3 (OATP1B3 in Q3) are known sorafenib transporters and/or partici-
pate in sorafenib metabolism in the liver [45,46,50,57], and altered or aberrant expression of these transporters might modulate the therapeutic efficacy of sorafenib and/or activate the TXNRD1 and NRF2/KEAP1 pathways to increase oxidative stress and tumorigenicity in HCC. Therefore, combination therapy with sorafenib and NRF2/TXNRD1 inhibitors could be a promising strategy to improve HCC therapy [45,46,50,57]. Other known sorafenib-altered pcHCC genes, such as SLC7A11 (in Q4), are key modulators of ferroptosis, which has led to the application of another ferroptosis inducer, artesunate, in sorafenib combination therapy for HCC [58]. AURKB (Aurora kinase B, in Q4) is a known HCC oncogene, and its inhibitor was combined with sorafenib to further induce HCC tumor shrinkage [54] (Fig. 4B). Collectively, the results showing the different mechanisms to support sorafenib combination therapies (Table 1) provide a better understanding and rationale for exploring innovative mechanisms of sorafenib-altered pcHCC genes to further develop strategies for the improvement of sorafenib combination therapy.

2.6. Combination treatment with sorafenib and shRNAs of NCAPG or CENPW synergized suppression of cell viability by diminishing p38/STAT3 signaling

To explore the potential of innovative targets among these pcHCC genes for sorafenib combination therapies in HCC, we investigated the mechanistic roles and testing therapeutic efficacy of two pcHCC genes, NCAPG (non-SMC condensin I complex subunit G, Fig. 3C) and CENPW (centromere protein W, Fig. 3D), which are involved in HCC cell proliferation but have not been studied in sorafenib combination therapy. In addition to the association of these genes with poor prognosis in HCC patients, aberrant upregulation of NCAPG and CENPW was significantly associated with extrahepatic metastasis (BCLC stage C) (Supplementary Fig. 3A and C) and tumor size but not with venous invasion (Supplementary Fig. 3B and D) in HCC patients. With these supportive results, we continued to evaluate the suppressive effects of knocking down the expression of upregulated NCAPG and CENPW with specific short hairpin RNAs (shRNAs) and then investigated the impact on downstream cell proliferation signaling in HCC cells to validate the sorafenib combination therapy (Fig. 5).

First, we confirmed the upregulated expression of NCAPG and CENPW in locally recruited HCC tumors compared to their adjacent normal tissues (n = 21 pairs) through RT–qPCR experiments (Fig. 5A and B) and knocked down NCAPG and CENPW with their corresponding shRNAs to evaluate their roles in the predicted functions of HCC cell proliferation and migration. As expected, knockdown of NCAPG (shNCAPG #2 and #3) and CENPW (shCENPW #3 and #4) with two independent shRNAs in two HCC cell lines, Mahlavu and HCC36, significantly diminished cell proliferation and decreased cell migration, as shown by transwell migration

Fig. 3. Gene set enrichment analysis (GSEA) of pcHCC genes. (A) Heatmap of the normalized enrichment score (NES) compared with GSEAs of the pcHCC genes, differentially expressed genes (DEGs) in all liver cancer microarrays, and DEGs in TCGA-LIHC. Significance was defined at P < 0.05. (B) Kaplan–Meier plots of downregulated metabolism-related (n = 89) and upregulated cell proliferation-related (n = 116) pcHCC genes.
assays (Fig. 5C–F). Our results suggested that upregulated expression of NCAPG and CENPW plays important roles in HCC tumor growth and that cell migration leads to tumor progression.

Second, to better understand the molecular pathways involved in NCAPG- and CENPW-driven HCC tumor progression, we examined the protein expression in the MAPK and STAT3 pathways, which are known for their involvement in HCC cell proliferation, survival and migration, through Western blotting analysis [59,60]. Our results not only confirmed the knockdown efficiency of shRNAs against CENPW and NCAPG but also validated the reduction in cell proliferation by decreasing the expression of the cell proliferation markers PCNA and MCM2 (Fig. 5G and 5H). Interestingly, knockdown of NCAPG and CENPW with shRNAs consistently diminished the expression of p-STAT3 (pSer727) and MAPK p-p38 (pThr180/pTyr182) signaling but not ERK/p-ERK (pThr202/Tyr204) and JNK/p-JNK (pThr183/Tyr185) MAPK signaling, as shown by the Western blotting analysis (Fig. 5G and H). Previous studies indicated that the p38/STAT3 axis (but not the ERK/JNK MAPK signaling pathway) is involved in the expression of proinflammatory cytokines (e.g., IL6) and the stress-induced acute phase response of HCC cells [61–63]. Nevertheless, the biological functions of NCAPG and CENPW in the p38/STAT3 axis in HCC might be different because knockdown of NCAPG diminished the expression of p-p38, p-STAT3 and STAT3 but not the overall protein level of p38, and knockdown of CENPW reduced the expression of p-p38, p38, and p-STAT3 but not the total protein level of STAT3.

Finally, we conducted combination treatments of sorafenib with shRNAs of NCAPG or CENPW to identify the viability of HCC cells. Our results demonstrated that knockdown of either NCAPG or CENPW in Mahlavu and HCC36 cells conferred significant hypersensitivity to sorafenib treatment in a dose-dependent manner (Fig. 6A–D). Moreover, sorafenib treatment of shRNA-knocked down NCAPG or CENPW Mahlavu cells further decreased the expression of p-p38 and p-STAT3 in a dose-dependent manner, as shown by the Western blotting analysis (Fig. 6E and F). Together, our results suggest that NCAPG and CENPW, which suppress p38/STAT3 signaling, are potential targets for sorafenib combination therapies in HCC. In addition, our results suggest that the 664 pcHCC genes might contain innovative targets and pathways for developing therapeutic agents for HCC sorafenib combination therapies.

3. Discussion

In this study, we conducted a comprehensive comparative genomic analysis of large-scale transcriptome datasets (5410 human HCC and 974 mouse liver cancer) to identify concordantly expressed HCC genes associated with altered clinical features in HCC progression and patient prognosis (pcHCC genes) and reveal innovative targets for sorafenib combination therapy. Although HCC transcriptome analyses have been conducted in recent years with a focus on altered cell proliferation and/or metabolic reprogramming with different approaches [18,64–66], to our knowledge, our results are the first to indicate that the enriched signatures harbored innovative targets (~44%) suitable for developing therapeutic agents/inhibitors in sorafenib combination therapy. We provided lines of evidence from in silico analyses (Fig. 4 and Table 1) and experimental studies of the selected pcHCC genes NCAPG and CENPW (Figs. 5 and 6) to support our hypothesis. Experimentally, we revealed that the proinflammatory and stress-related p38/STAT3 axis, but not conventional ERK/JNK MAPK signaling, plays critical roles in HCC progression and is suitable as a target for sorafenib combination therapy. Moreover, we identified 664 pcHCC genes harboring numerous innovative HCC targets.
Fig. 5. Functional and biochemical examinations of CENPW and NCAPG in HCC cell lines. (A, B) NCAPG (A) and CENPW (B) were upregulated in the local HCC tumors and corresponding normal pairs (n = 21) based on RT-qPCR. (C–E) NCAPG knockdown by two shRNAs reduced cell proliferation and migration in the (C) Mahlavu and (D) HCC36 HCC cell lines, as shown by bar graphs and representative migrated cells after crystal violet staining. CENPW knockdown by two shRNAs reduced cell proliferation and migration in the (E) Mahlavu and (F) HCC36 HCC cell lines, as shown by bar graphs and representative migrated cells after crystal violet staining. (G, H) Western blotting analysis of the representative markers MCM2 and PCNA for cell proliferation and MAPK signaling for the ERK, JNK and p38, and STAT pathways after shRNA knockdown of (G) NCAPG and (H) CENPW in Mahlavu cells. Error bars are the mean ± s.d. **P < 0.001 and ***P < 0.0001, determined by two-tailed Student's t test (95% confidence interval).

Table 1
List of known targets and modalities of the sorafenib combination HCC therapies.

| Target genes | Quadrants | Agent for sorafenib combination therapies | Mechanism of sorafenib HCC combination therapy | Ref |
|--------------|-----------|------------------------------------------|-----------------------------------------------|-----|
| HK2          | Q1        | Dichloroacetate                          | Sensitizes sorafenib-res. cells               | [37]|
| CD24         | Q1        | Gedatolisib (PKI-587)                    | Inhibits CD24+ cells                          | [38]|
| PCNA         | Q1        | TR3 synergist (BM-06)                    | Suppresses PCNA expression                    | [39]|
| DNMT1        | Q1        | AuNps-anti-miR221                        | Inactivates DNMT1 signaling                   | [40]|
| EZF1         | Q1        | S-1                                      | Downregulates EZF1                            | [41]|
| LOX          | Q1        | β-aminopropionitrile                     | Diminishes angiogenesis                       | [42]|
| AKR1B10      | Q1        | Epalrestat                               | Enhances sorafenib effect                     | [43]|
| FOXO3        | Q3        | Anti-mRNA27a                             | Upregulates FOXO1-related apoptosis           | [44]|
| SLC27A5      | Q3        | Brusatol                                 | Sensitizes cells to sorafenib                | [45]|
| SLCO1B3      | Q3        | SLCO1B3 deficient                        | Reduces sorafenib clearance                   | [46]|
| AR           | Q2        | PT-2385                                  | Increases AR to inhibit growth                | [47]|
| TXNIP        | Q2        | MEAN                                     | Increases TXNIP to inhibit tumor             | [48]|
| HGF          | Q2        | Vitamin K                                | Reduces HGF-stimulated growth                | [49]|
| PKC1         | Q2        | Auranofoxin                              | Sensitizes sorafenib-apoptosis                | [50]|
| HTATIP2      | Q4        | Metformin                                | Upregulates HTATIP2/downregulates Thioredoxin | [51,52]|
| CCNB1        | Q4        | MBRI-001                                 | Downregulates CCNB1                           | [53]|
| TXNRD1       | Q4        | Brusatol                                 | Downregulates TXNRD1/up KEAP1/NRF2           | [45]|
| PKC1         | Q4        | PHA-79358                                | Suppresses AURKB                             | [54]|
| CDK4         | Q4        | Palbociclib                              | Suppresses CDK4/6                            | [55]|

1758
(≈44%) for developing HCC biomarkers associated with patient prognosis, thus revealing innovative signaling pathways in tumor progression and identifying theranostic targets to predict drugs/agents for sorafenib combination therapies to potentially prolong the life of HCC patients.

With the increasing incidence and mortality of HCC worldwide, rapid developments have been made in systemic therapies for advanced HCC and several therapeutic options have been FDA-approved as first-line therapies, including sorafenib [8,9], lenvatinib [10], and atezolizumab plus bevacizumab [12]. Other antiangiogenic multikinase inhibitors, such as regorafenib and cabozantinib, as well as the antibody drug ramucirumab, which targets anti-vascular endothelial growth factor-2 (VEGF-R2), and immune checkpoint inhibitors (ICIs) against PD-1 and cytotoxic T lymphocyte antigen 4 (CTLA-4), were approved for the second-line treatment of HCC [11,67,68]. Despite these therapeutic advances, only approximately 25% of HCC patients show a therapeutic response and improved overall survival, and the current therapeutic regimens remain ineffective for prolonging the life of most HCC patients [69]. Although sorafenib therapy in HCC offers some benefits, including a 2.8-month longer median overall survival than the placebo, endeavors to improve HCC sorafenib therapy, including the discovery of therapeutic biomarkers and combination therapy with other drugs, remain critical due to the limited availability, affordability and effectiveness of sorafenib as a single-drug HCC therapy.

For the discovery of therapeutic biomarkers of sorafenib, since frequent substitutional driver mutations with therapeutic options have not been identified after large-scale sequencing efforts in human HCC genomes [14], copy number alterations, especially gene amplification, leading to increasing expression of target genes have attracted specific attention to select subgroups of HCC patients for targeted sorafenib therapy. Indeed, the FGF3/FGF4 amplicon at chromosomal region 11q13 [70] and the VEGFA amplicon at chromosomal region 6p21.1 [71] were amplified in ≈2% and 7~10% of human HCC genomes, respectively, and they encode the potential oncogenic driver proteins FGF4 and VEGF-A, which showed better responses to sorafenib treatment. Although copy number alterations in the HCC cancer genome commonly affect a small population of cancer patients, the identification of therapeutic targets/biomarkers could stratify subgroups of HCC patients to develop more precise HCC therapies. Notably, we also explored the correlations of the 664 aberrantly expressed pcHCC genes with copy number alterations (CNAs) in the HCCs of the TCGA_LIHC dataset (Supplementary Fig. 4). The lack of statistical associations between CNAs and aberrant gene expression of the 664 pcHCC genes (r = 0.0058, P value = 0.1373) implied the low potential for developing pcHCC genes as CNA-based therapeutic biomarkers in HCC.

Although some comparative genomics approaches have been applied for decades to develop best-fit mouse models of cancer subtypes and identify driver genes in cancers, including HCC [21,23,72,73], a systematic and detailed explorations of comparative HCC genes implicated in the core HCC pathophysiological and clinical features and patient prognosis and even the targets of sorafenib combination therapy are lacking. Based on the aberrant enrichment of upregulated cell proliferation and downregulated lipid and xenobiotic metabolism-related genes of the 664 pcHCC genes, we hypothesized and systematically explored the underlying molecular mechanisms of sorafenib therapies in HCC. In addition to matching the divergently acting molecular mechanisms of sorafenib combination therapies reported previously (Table 1), we also selected two pcHCC genes, NCAPG and CENPW, because the aberrant upregulation of these genes is associated with the clinical features and prognosis of HCC patients (Supplementary Fig. 3A–D); moreover, these genes have not been previ-
ously targeted in sorafenib combination therapies to explore the oncogenic mechanisms and develop therapeutic strategies. NCAPG encodes a non-SMC (structural maintenance of chromosome) condensin I complex subunit G protein that has been shown to be upregulated in HCC to activate the PI3K/AKT pathway and enhance cell proliferation, and it has been associated with poor prognosis in HCC patients [74–79]. Upregulated CENPW, the centromere protein W, which is sometimes also called cancer upregulated gene 2 (CUG2), was found to enhance cancer epithelial to mesenchymal transition (EMT) and stemness via activation of the canonical TGF-β signaling pathway and tumor progression in other cancers [80,81]; however, its role in HCC is unknown. Neither the upregulation of NCAPG nor CENPW or related inhibitors has been shown to play a role in sorafenib combination therapy in HCC. Interestingly, we found that a rarely studied p38/STAT3 proinflammatory/stress-related axis (not JNK/ERK signaling) was required to sustain HCC oncogenic features. The combination of shRNAs of NCAPG or CENPW with sorafenib in the treatment of HCC cells showed synergetic suppression of oncogenic features and downstream signaling, further suggesting that pCHCC genes are an important resource as theranostic targets for early biomarker detection and therapeutic agents/inhibitors for sorafenib combination therapy to improve HCC therapy.

Because of the increasing need for cancer therapy worldwide, including HCC therapy, and the superior therapeutic benefits of combination therapy [12,82–84], systematic exploration of sorafenib action mechanisms and innovative targets for combination therapy is crucial for improving HCC therapy. Our systematic prediction of potential targets among 664 pCHCC genes for the sorafenib combination therapy provides rationales and resources for further improving HCC therapy with the following features. First, we provide a comprehensive landscape of predictive sorafenib combination therapies with divergent mechanisms based on different scenarios of altered HCC gene expression (Fig. 4 and Table 1), and the findings were validated using selected target genes (Fig. 6). Second, the innovative pCHCC targets identified in our study could also be biomarkers for predicting sorafenib therapeutic responses for tumor recurrence. Finally, a similar approach could be applied to other cancer types for the development of therapeutic agents/inhibitors to improve the combination therapy of other antiangiogenic multikinase inhibitors, and such approaches could be validated in comparative mouse cancer models. Our approach of applying concordantly expressed comparative cancer genes to forecast targets and therapeutic agents in combination cancer therapy could be difficult to implement due to the limited availability of transcriptomic datasets with clinical features derived from comparative cancer models and cancer patients treated with and without therapeutic agents. Nevertheless, with increasing cancer incidence and mortality predicted worldwide in the coming decade, the successes of combination cancer therapies reported in multiple cancers will encourage more clinical trials on combination therapies with the goal of reducing the toxicity and cost to prolong the survival of cancer patients.

4. Conclusions

To improve HCC therapies and meet emerging needs worldwide, we conducted a large-scale comparative transcriptome analysis and identified 664 pCHCC genes (~44% are innovative targets) associated with prognostic clinical features and enriched driver gene signatures suitable for developing sorafenib combination therapies. We provided lines of evidence to demonstrate the divergent mechanisms of sorafenib combination therapies in HCC and experimentally validated selected pCHCC genes by reducing their expression in HCC cells via a diminished innovative p38/STAT3 axis to hypersensitize HCC cells in sorafenib-combined treatments. We provided important insights on 664 pCHCC genes, and they include innovative targets and molecular signaling factors suitable for systematic targeting in sorafenib HCC combination therapy, which has the potential to prolong the life of HCC patients.

5. Materials and methods

5.1. Data sources and preprocessing

The transcriptome datasets were downloaded from the NCBI Gene Expression Omnibus [85]. We selected transcriptomes derived from tumors of human hepatocellular carcinoma (HCC)-only and mouse liver cancer models but excluded transcriptomes from cell lines (Supplementary Tables 1 and 2). The majority of mouse transcriptomes were annotated as HCC (~70%) or liver cancer (~30%) in genetically modified models with and without carcinogen induction, as detailed in Supplementary Table 2. The ratio of tumor-versus-normal samples for each probe was calculated for each dataset. If there was no normal sample in a dataset, a pool of normal samples was constructed from normal samples from other datasets of the same platform. Two independent HCC datasets from iCOD and TCGA_LIHC (the level 3 RNA-Seq data of HCC tumors) were downloaded based on the original report [27] and The Cancer Genome Atlas [86] using the R package TCGAbiolinks (https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html) [87].

5.2. Integrated meta-analysis of HCC and mouse genes

All probes were mapped to the gene ID in the Ensembl database (https://www.ensembl.org, build 92), and mouse Ensembl gene IDs were then mapped to human Ensembl gene IDs [88]. An average ratio was calculated for the multiple probes mapped into one Ensembl gene ID. For all tumor/normal ratios, log2 transformations were performed, followed by the Z-score transformation of each sample to standardize data across samples in all datasets [89]. Student’s t-test was performed for each Ensembl gene ID.

5.3. Determination of comparative differentially expressed genes (DEGs) and gene set enrichment analysis (GSEA) in HCC

To determine the comparative DEGs, we defined the upregulated probes when the processed log2 tumor/normal ratios were more than 1 and the downregulated probes when the ratios were less than −1. The percentage of DEGs was calculated from the sum of upregulated or downregulated labels versus the total sample numbers. An adjusted percentage for defining the upregulated and downregulated genes was calculated using a formula (percentage of upregulated labels minus percentage of downregulated labels) for each Ensembl gene ID. For assembled gene IDs with <25% presented in the samples, those with a p value of more than 0.05 in Student’s t-test, <5% total altered sample percentage, and 5% to −5% adjusted regulated percentage were filtered out. Only the Ensembl gene IDs having the same regulatory trend in both human and mouse samples were selected as comparative DEGs. Gene set enrichment analysis (GSEA) was applied to detect enriched pathways of the DEGs with FDR < 0.05 and P value <0.05 for consideration of significant enrichment [90].

5.4. Archived HCC samples

 Archived HCC tissues and the corresponding normal tissues (n = 21) were collected from National Taiwan University Hospital with IRB approval [17]. Tissue was harvested after curative HCC
surgery, frozen in liquid nitrogen, and stored in a −80 °C freezer immediately after being sliced into small pieces.

5.5. RNA isolation, RT-PCR and quantification of RNA expression

Total RNA was extracted from HCC tissues using TRIzol (Invitrogen) according to the manufacturer’s instructions. RNA purity was assessed with a NanoDrop spectrophotometer (Thermo Scientific). RNA was reverse-transcribed into cDNA with oligo-dT primers using a Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Scientific). RT-PCR was performed with Taq DNA Polymerase Master Mix RED (Ambion). PCR cycling conditions were 95 °C for 30 s, 60 °C for 30 s and 72 °C for 20 s for 40 cycles. The PCR products were separated through gel electrophoresis with DNA View (Tools Biotech) in a 1.5% agarose gel and identified through UV exposure. RNA expression quantification was performed with GelQuant. NET software provided by biochemlabsolutions.com. Target gene expression of certain HCC samples was normalized to the internal control GAPDH expression. The list of primers used for RT-PCR is included in Supplementary Table 11.

5.6. Transwell migration assay

Cell migration assays were conducted as described previously [84]. Each condition was performed in triplicate wells with seeding of a total of 3 × 10⁴ cells/well for Mahlavu or 8 × 10⁴ cells/well for HCC36 HCC cell lines. After 24 h, the migrated cells were stained with Giemsa solution (Merck) and counted in 100 × microscopic fields with ImageJ (NIH, USA).

5.7. Cell viability assays

Cell viability was assessed in triplicate wells for each condition using the alamarBlue assay (BioSource International) [84]. A total of 1 × 10⁴ Mahlavu or HCC36 HCC cells/well were seeded in 6-well plates and incubated in a 37 °C incubator. Cell viability at days 0, 1, 3, 5, 7 and 9 post-seeding was analyzed by detecting the absorbance using a microplate reader. Sorafenib dissolved in dimethyl sulfoxide (DMSO) at various concentrations was added 0, 1, 3, 5, 7 and 9 post-seeding was analyzed by detecting the absorbance using a microplate reader. Sorafenib dissolved in dimethyl sulfoxide (DMSO) at various concentrations was added

5.8. Short hairpin RNA (shRNA)-mediated gene silencing

The productions of shRNA lentivirus particles were performed according to previous report [91]. The following shRNA vectors were used for silencing gene expression: shCENPW #3 (TRCN0000142180), shCENPW #4 (TRCN0000143715), shNCAPG #2 (TRCN0000145160) and shNCAPG #3 (TRCN0000144644) (National RNAi Core Facility, Taiwan). Transduction of Mahlavu or HCC36 cells with shRNA lentiviral particles was performed in 6-well plates containing the transduction adjuvant polybrene (8 μg/ml). Stable shRNA-expressing HCC cells were selected using puromycin for 2 weeks. Knockdown efficiency was assessed with Western blot.

5.9. Western blot analysis

The following antibodies against specific proteins were used for Western blot analysis: Actin (A00702, GenScript), CEPNW (SC-137988), NCAPG (AP19113a, Abgent), MCM2 (BS1221, Bioworld), PCNA (BS1289, Bioworld), p-ERK (9101, Cell Signaling), ERK (9102, Cell Signaling), p-JNK (9255, Cell Signaling), JNK (9252, Cell Signaling), p-p38 (1229–1, Epitomics), p38 (54419, AnaSpec), p-STAT3 (9134, Cell Signaling) and STAT3 (Sc-482, Santa Cruz, USA). Total protein was extracted from the cells using RIPA buffer as described previously [84]. Quantification of total protein lysate was analyzed using a BCA protein assay kit (Pierce Chemical). Protein from each condition (20 μg) was separated with 8 ~ 12% SDS-PAGE and then blotted onto PVDF membranes (Millipore). The protein-blotted PVDF membranes were further probed with specific antibodies (1:5000 dilution) overnight at 4 °C. The membranes were washed and then reprobed with HRP-conjugated secondary antibodies (1:10,000) at room temperature for 1 hr. The signal on protein-blotted membranes was visualized using ECL (Enhanced Chemiluminescence) reagents (SuperSignal, Pierce Chemical) and autoradiography films (Kodak Rochester, NY).

5.10. Statistical analysis and data visualization

All in vitro conditions were performed in triplicate, and values are shown as the mean ± 95% confidence interval (CI). The differences between groups were determined using Student’s t-test, and statistical significance was considered when P < 0.05. All analyses were performed in the R statistical programming environment. All plots were produced with the ggplot2 package (https://ggplot2.tidyverse.org/). All scripts for data analysis and visualization are available upon request.

Declaration of Competing Interests

The authors declare no conflicts of interest.

Acknowledgement

RNAi reagents were obtained from the National RNAi Core Facility, supported by the Ministry of Science and Technology (MOST), Taiwan. We thank the Common Equipment Core of IBMS and Academia Sinica of Taiwan, including the Light Microscopy Core Facility and DNA sequencing facility (AS-CFII-108-113 and AS-CFII-108-115).

Author contributions

C.M.H. performed the experiments, analyzed the results and wrote the manuscript; K.T.L., D.L.G., R.S. and S.S.L. performed the experiments and analyzed the results; W.H.S. and Y.S.J. supported the work and edited and revised the manuscript.

Funding

Academia Sinica and Ministry of Science and Technology of Taiwan supported our work (MOST 107-0210-19-01, 108-2321-B-001-010, and 109-2320-B-001-014-MY3), CRC grants of IBMS (IBMS-CRC108-P02) and AS investigator award (AS-IA-109-L03) and AS-KPQ-111-KNT for Y.-S.J. and Chang Gung Memorial Hospital Research Program (CMRPD1H0351, CMRPD1J0111) for W.-H.S.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2022.04.008.

References

[1] Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380(15):1450–62.
[2] Lange N, Dufour JF. Changing epidemiology of HCC: how to screen and identify patients at risk? Dig Dis Sci 2019;64(4):903–9.
[3] Organization WH. Projections of mortality and causes of death, 2016 to 2060. (http://www.who.int/healthinfo/global_burden_disease/projections/en/).
[4] Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6.
Brandi G, Di Federico A, Rizzo A, De Lorenzo S, Vasuri F, Brocchi S, et al. The
Tuo L, Xiang J, Pan X, Gao Q, Zhang G, Yang Y, et al. PCK1 downregulation
Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, et al. A synthetic dsRNA,
Vavricka SR, Jung D, Fried M, Grützner U, Meier PJ, Kullak-Ublick GA. The
Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution
Guo Z, Cao M, You A, Gao J, Zhou H, Li H, et al. Metformin inhibits the
Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles-loaded anti-miR221
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus
Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, et al. Compromised
Liu Y, Lou G, Norton JT, Wang C, Kandela I, Tang S, et al. 6-Methoxyethylamino-
Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in
Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, et al. Gene expression
Wang Z, Zhao K, Zhang Y, Duan X, Zhao Y. Anti-GPC3 antibody tagged cationic
Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, et al. Increasing AR by HIF-2α
Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of
Balmain A, Harris CC. Carcinogenesis in mouse and human cells: parallels and
Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, et al. SLC27A5 deficiency
Ha TY, Hwang S, Hong HN, Choi YI, Yoon SY, Won YJ, et al. Synergistic effect of
Su WH, Chun Y, Xiong XY, Lin T, He Y, Cui Z, et al. miR-328-3p inhibits miR-192
Jin YY, Han C, Geng N, Liu YR, Zheng LY, Zhu WJ, et al. AKR1B10 inhibitor
Deng M, Li L, Yuan S, Li W. Antitumor activity of the microtubule
Shimokawa K, Mogushi K, Shoji S, Hiraishi A, Ido K, Mizushima H, T, et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastroenterol 2009;43(2):191–5.
Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 2013;108(1):72–81.
Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, et al. PKR-587
and sorafenib alone in combination on inhibition of liver cancer stem cell proliferation. J Surg Res 2013;185(1):235–30.
Xu YY, Chen L, Wang GL, Zhou JM, Zhang XY, Wei YZ, et al. A synthetic dsRNA, a TLR3 pathway agonist, combined with sorafenib enhances HCC in vitro and in vivo. BMC Cancer 2013;13:27.
Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles–loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2019;16(12):1541–50.
Zhuo Y, Yin XY, Lai Z, Hou X, Cai JP, Hao XY, et al. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Cancer Chemother Pharmacol 2013;71(5):1255–64.
Yang M, Liu J, Wang F, Tian Z, Ma R, Li Z, et al. Lysyl oxidase assists tumor-initiating cells to enhance angiogenesis in hepatocellular carcinoma. Int J Oncol 2019;54(4):1398–408.
Jin YY, Han C, Geng N, Li YR, Zheng LY, Zhu WJ, et al. ATRK1B10 inhibitor enhances the inhibitory effect of sorafenib on liver cancer xenograft. Zhonghua Gan Zang Bing Za Zhi 2019;7(1):39–44.
Wang Z, Zhao K, Zhang Y, Duan X, Zhao Y. Anti–GPC3 antibody tagged cationic liposomes as a delivery of the antibody for the therapy of anti-miRNA27a and sorafenib in liver cancers. Pharm Res 2019;36(10):1430–40.
Gao Q, Zhang G, Zheng Y, Yang Y, Chen C, Xia J, et al. SL-C27A5 deficiency activates NF2X/TRXN1 pathway by increased lipid peroxidation in HCC. Cell Death Differ 2020;27(3):1086–1094.
Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib–glucuronide. Clin Cancer Res 2013;19(6):1458–66.
Xu J, Guo L, Chen J, Liu BA, et al. Increasing AR by HIF2-α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 2017;8(10):e3059.
Liu ZQ, Lu G, Jiang H, Tang S, et al. 6-Methoxyethylaminodione inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB J 2017;31(12):5453–65.
Ha TY, Hwang S, Hong HH, Choi YI, Youn SY, Won YJ, et al. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. Anticancer Res 2015;35(4):1895–95.
Tuo L, Jiang X, Pan X, Gao Q, Zhang Y, et al. PCK1 downregulation promotes TNFR1 expression and hepatoma cell growth via the Nrf2/Keap1 pathway. Front Oncol 2018;8:611.
Schulte L, Scheiner B, Voigtlander T, Koch S, Schwietzer N, Marhenke S, et al. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int 2019;39(4):714–26.
Guo Z, Cao M, You A, Gao J, Zhou H, Li H, et al. Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer Sci 2016;107(4):507–13.
Deng M, Li L, Zhao J, Yuan S, Li W. Antitumor activity of the microtubule inhibitor MBI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib. Cancer Chemother Pharmacol 2018;81(3):853–62.
Bentson D, Keller G, Quasas A, Schrader J, Gontarewicz A, Balabanov S, et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11(9):934–44.
Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci 2014;59(8):1688–97.
Herraiz E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, et al. Expression of SLC22A1 variants may affect the response of hepatocellular...
carcinoma and cholangiocarcinoma to sorafenib. Hepatology 2013;58 (3):1065–73.

[58] Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 2020;42(2):301–10.

[59] Lee C, Cheung ST. STAT3: an emerging therapeutic target for hepatocellular carcinoma. Cancers (Basel) 2019;11(1):1646.

[60] Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011;21(1):10–20.

[61] Lejeune D, Dumoutier L, Constantinescu S, Krujiv W, Schurring J, Renaud J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat Hepatoma Cell Line: pathways that are shared with and distinct from IL-10. 2002;277(37):33676–82.

[62] Schurring J, Jonk LJ, Dokter WH, Vellenga E, Krujiv W. Interleukin-6-induced STAT3 transactivation and Sert27 phosphorlyation involves Vav, Rac-1 and the kinase S6K-1/MK2 as signal transduction components. Biochem J 2000;347 Pt 1(Pt 1):89–96.

[63] Zabournian A, Zipori D, Krupsky M, Ben-Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999;18(26):3886–93.

[64] Allain C, Angenard G, Clement B, Couloumar C. Integrative genomic analysis identifies the core transcriptional hallmarks of human hepatocellular carcinoma. Cancer Res 2016;76(21):6374–81.

[65] Wan Z, Zhang X, Luo Y, Zhao B. Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses. Genet Test Mol Biomarkers 2019;23(11):766–77.

[66] Rodrigues RR, Barry CT. Gene pathway analysis of hepatocellular carcinoma genomic expression datasets. J Surg Res 2011;170(1):e65–92.

[67] Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib [KEYNOTE-224]: a non-randomised, open-label, phase 2 trial. Lancet Oncol 2018;19(7):940–52.

[68] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymouth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16(10):589–604.

[69] de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell 2020;38(3):326–33.

[70] Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, et al. FGFR3/ FGFR4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013;57(4):1407–15.

[71] Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGCF-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014;4(6):730–43.

[72] Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenic approach. Cell 2006;125(7):1253–67.

[73] Bow M, Pyle RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, et al. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2018;115(42):E9879–88.

[74] Bayo J, Fiore EJ, Domínguez JM, Real A, Malvigin M, Rizzo M, et al. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol 2019.

[75] Li B, Pu K, Wu X. Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis. J Cell Biochem 2019.

[76] Wang Y, Gao B, Tan PY, Handoko YA, Sekar K, Devisagamani A, et al. Genome-wide CRISPR knockdown screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. FASEB J 2019;fj201802213RR.

[77] Yan H, Li Z, Shen Q, Wang Q, Tian J, Jiang Q, et al. Aberrant expression of cell cycle and metabolism related genes contributes to hepatocellular carcinoma occurrence. Pathol Res Pract 2017;213(4):316–21.

[78] Zhang Q, Su R, Shan C, Gao C, Wu P. Non-SMC Condensin I Complex, Subunit G (NCAPG) is a novel mitotic gene required for hepatocellular cancer cell proliferation and migration. Oncol Res 2018;26(2):269–76.

[79] Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, et al. NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Onco Targets Ther 2019;12:8537–52.

[80] Cheon Y, Lee S. Two major alternative splice variants of beta-TrCP1 interact with CENP-W with different binding preferences. Genes Genomics 2019;41 (2):167–74.

[81] Kaowinn S, Seo EJ, Heo W, Bae JH, Park EJ, Lee S, et al. Cancer upregulated gene 2 (CUG2), a novel oncogene, promotes stemness-like properties via the NPM1-TGF-beta signaling axis. Biochem Biophys Res Commun 2019;514(4):1278–84.

[82] Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013;31 (12):1592–605.

[83] Park SR, Davis M, Doroshow JH, Kummarr S. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol 2013;10(3):154–68.

[84] Lin KT, Wang YW, Chen CT, Ho CM, Su WH, Jou YS. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin Cancer Res 2012;18(17):4691–701.

[85] Barrett T, Willhite SE, Ledoux P, Evangelista C, Kim IF, Tomasevsky M, et al. Soboleva A, NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013;41(Database issue):D991-995.

[86] Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, et al. International network of cancer genome projects. Nature 2010;464 (7291):993–8.

[87] Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAholinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 2016;44(8):e71.

[88] Yates AD, Achuthan P, Akannni W, Allen J, Allen J, Alvare-Jarreta J, et al. Nucleic Acids Res 2019;48(D1):D682–8.

[89] Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. J Mol Diagn 2003;5(2):73–81.

[90] Subramanian A, Tamayo P, Mootha VK, Muklerjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102(43):15545–50.

[91] Wang YW, Tu PH, Lin KT, Lin SC, Ko FY, Jou YS. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia 2011;13(8):704–15.